Worldwide Clinical Trials’ Director of Global Patient Recruitment and Retention, Barbara Zupancic, will present “Improving Patient Engagement in Alzheimer’s Disease Trials” today at the Outsourcing in Clinical Trials (OCT) Southern California 2017 conference in La Jolla, CA. The presentation follows the challenge Worldwide Clinical Trials President and COO, Peter Benton, presented to drug sponsors at OCT New England on September 6, “Challenge CROs with 5 Tough Questions to Improve Partnership Value.”
Using Alzheimer’s Disease (AD) as an example, Zupancic will encourage Southern California’s most prominent biotech, pharmaceutical and medical device companies to ask their CRO partners: “What is your strategy to identify, engage and keep patients and caregivers interested in study participation and adherent with study procedures?” The discussion will reflect on four relevant themes for CROs to consider when embarking on AD studies to ensure value from the strategic partnership:
- Discussing Alzheimer’s disease to decipher complexities in clinical study recruitment efforts
- Evaluating the emotional and social needs of caregivers to determine how they color the patient experience
- Assessing whether it makes sense to use professional marketing techniques or if patients and caregivers are turned off by a study that appears too commercial
- Deciphering challenges of enrolling patients with mild cognitive impairment in the growing field of clinical research in earlier stages of Alzheimer’s disease
Zupancic will carry the discussion further during another interactive session at OCT Nordics on October 10th, 2017 at 9:30am in Copenhagen, Denmark, where she will use the emerging opportunities in Orphan Disease drug development as an example to facilitate strategic opportunities for patient recruitment and engagement.
For more details, see below or register for event:
- WHAT: Outsourcing in Clinical Trials (OCT) Southern California 2017
- WHEN: September 27th, 2017, La Jolla, Southern California, US; 11:15 am PT
- WHERE: Presentation: Improving Patient Engagement in Alzheimer’s Disease Trials
- WHO: Barbara Zupancic, Director, Global Patient Recruitment and Retention, Worldwide Clinical Trials
Connect with Worldwide Clinical Trials:
- Tweet: @Worldwidetrials #UncommonCRO with your challenging question
- Reserve a place today! http://www.arena-international.com/octsocal
- Follow us on Twitter: @worldwidetrials
- Find us on LinkedIn: https://www.linkedin.com/company/worldwide-clinical-trials-inc-
About Worldwide Clinical Trials
Worldwide Clinical Trials employs more than 1,600 professionals around the world, with offices in North and South America, Eastern and Western Europe, Russia and Asia. Founded by physicians committed to advancing medical science, Worldwide is out to change how the world experiences CROs – in the best possible way. From Early Phase and Bioanalytical Sciences through Late Phase and post approval, we provide world-class, full-service drug development services. With infrastructure and talent spanning 60 countries, we execute predictable, successful studies with operational excellence. We never compromise on science or safety. We’re never satisfied with the status quo. We’re the Cure for the Common CRO. For more information, visit Worldwide.com.
